Reprogrammed Interchange Llc Sells 449,226 Shares of Vor Biopharma (NYSE:VOR) Stock

Key Points

• Reprogrammed Interchange LLC sold 449,226 shares of Vor Biopharma stock for $898,452, representing a 1.28% decrease in their position as a major shareholder.
• Vor Biopharma stock has traded down 10.4%, currently sitting at $1.80, with a market capitalization of $228.03 million and notable trading activity of over 6 million shares.
• Analysts have a consensus rating of "Moderate Buy" for Vor Biopharma, with a target price of $6.07, indicating positive future expectations despite recent sell-offs.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $2.00, for a total value of $898,452.00. Following the completion of the sale, the insider directly owned 34,563,292 shares in the company, valued at approximately $69,126,584. This represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.82, for a total value of $637,000.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.97, for a total value of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The shares were sold at an average price of $1.93, for a total transaction of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total value of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total transaction of $1,229,410.47.
• On Tuesday, August 26th, Reprogrammed Interchange Llc sold 284,190 shares of Vor Biopharma stock. The stock was sold at an average price of $2.08, for a total transaction of $591,115.20.
• On Monday, August 25th, Reprogrammed Interchange Llc sold 387,346 shares of Vor Biopharma stock. The shares were sold at an average price of $2.12, for a total transaction of $821,173.52.

Vor Biopharma Trading Down 10.4%

VOR stock traded down $0.21 during mid-day trading on Wednesday, hitting $1.80. 6,041,745 shares of the company were exchanged, compared to its average volume of 7,646,274. Vor Biopharma Inc. has a 1-year low of $0.13 and a 1-year high of $3.29. The stock has a market capitalization of $228.03 million, a PE ratio of -1.09 and a beta of 2.05. The business has a 50 day simple moving average of $2.11 and a 200-day simple moving average of $1.12.

Institutional Trading of Vor Biopharma

Several large investors have recently bought and sold shares of VOR. XTX Topco Ltd acquired a new position in Vor Biopharma in the 2nd quarter valued at approximately $66,000. Goldman Sachs Group Inc. raised its holdings in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Vor Biopharma in the 1st quarter worth about $140,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma in the first quarter valued at $100,000. Finally, Money Concepts Capital Corp boosted its holdings in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after buying an additional 26,535 shares during the period. 97.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. HC Wainwright reissued a "buy" rating and issued a $3.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.07.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.